Skip to main content

False claims about miscarriage risk from Covid-19 vaccines are spreading online. They use a faulty interpretation of data

Sen. Cruz under fire for pushing false miscarriage rates from covid shot

(CNN) — Numerous studies have shown that Covid-19 vaccines are safe during pregnancy, but Republican senators have recently stirred up false and misleading claims that are now spreading on social media.

On Monday, Sens. Ron Johnson of Wisconsin and Rand Paul of Kentucky released a batch of text messages retrieved from Dr. Anthony Fauci’s former government phone as part of an investigation into the former health official’s leadership and actions during the Covid-19 pandemic – including messages in which he discusses the possible risks and safety of the vaccine during pregnancy.

These messages were a launching pad for the spread of inaccurate data, particularly claims about an 82% risk of miscarriage associated with Covid-19 vaccines. The incorrect figure spread online, including in a since-deleted post by Sen. Ted Cruz.

“This is a well-studied area. We knew this in 2021, that there wasn’t an increased risk, and now we have five more years of data. So it’s hard to believe we would miss a factor of eight increase in miscarriages,” Dr. Kevin Ault, an ob/gyn and president-elect of the National Foundation for Infectious Diseases, told CNN’s Erin Burnett on Thursday.

In a ​news release, Johnson references an exchange Fauci had in January 2021, in which he said that a second dose of a Covid-19 vaccine “theoretically could be associated with miscarriage in the 1st trimester,” as well as a criticism of a study that was published in the New England Journal of Medicine in April 2021.

In that study, researchers used data from a vaccine safety monitoring system to track outcomes for nearly 4,000 women enrolled in the registry who received Covid-19 vaccines in the early months of the rollout. Among them, the researchers identified 827 women who had a “completed pregnancy” — of which 712 were live births, 104 were spontaneous abortions or miscarriages, and 11 were other outcomes.

Initially, the researchers used this data to suggest that Covid-19 vaccines had a 12.6% miscarriage rate: 104 spontaneous abortions out of 827 completed pregnancies. That’s comparable with the average miscarriage rate of 10% to 20%, according to the Mayo Clinic.

However, a correction was issued in September 2021 to clarify that there was not enough data to calculate the risk of miscarriage using this particular study. The follow-up time was limited, so outcomes were unknown for the vast majority of participants, and the denominator of 827 completed pregnancies did not sufficiently represent the full sample of nearly 4,000 participants.

Still, that correction has been used to manipulate the study data in a way that significantly misrepresents miscarriage risk associated with Covid-19 vaccinations.

The researchers note that 700 of the completed pregnancies were in their third trimester when the mother was vaccinated, and they say that “any risk estimate would need to account for gestational week-specific risk of spontaneous abortion.” This meant “no denominator was available to calculate a risk estimate for spontaneous abortions.”

But in their claims about the risks of vaccination, critics are instead inaccurately constricting the denominator to exclude those 700 completed pregnancies in the third trimester. This would lead to an overestimation of miscarriage risk of 82%, based on a faulty calculation of 104 spontaneous abortions out of 127 pregnancies completed in the first or second trimester.

Experts in public health and pregnancy care emphasize that the benefits that the Covid-19 vaccine offers pregnant moms — and their babies — significantly outweigh any risk.

“It is without question that the benefits of the vaccine outweigh the risks, and the world’s literature on this topic includes hundreds of thousands of women,” said Dr. Brenna Hughes, chair of the Society for Maternal-Fetal Medicine’s Infectious Disease and Emerging Threats Committee.

The US Centers for Disease Control and Prevention cites dozens of studies on its website that come to the same conclusion.

”COVID-19 vaccination before and during pregnancy did not increase health risks for pregnant women or their babies,” the agency says. “In addition, studies have also shown that COVID-19 vaccination during pregnancy provides protection to both the pregnant woman and the baby.”

Hughes says that miscarriage concerns are common for pregnant women and that doctors are constantly discussing risks and benefits with their patients.

“When we offer any intervention in pregnancy, the first question is: ‘Is it safe for me? Is it safe for the baby?’”

With Covid-19 vaccines, the risks she tells people about most are a sore arm and some possible fatigue. The benefits are “incredibly clear,” she said, and outcomes are “quite the opposite of what of what some of this misinformation is saying.”

Covid-19 infection poses significantly more risk to pregnant women than the vaccines, experts say.

“We had hundreds of maternal deaths in 2021 due to Covid, and we still have severe illnesses, ICU stays, stillbirth, preterm deliveries related to those respiratory diseases,” Ault said. “Vaccination during pregnancy reduces the risk of all those things. So if somebody’s making decisions on these bad sources of information, that has a real downstream effect on maternal health.”

And Hughes says she worries that the resurfacing of misinformation about Covid-19 vaccines may leave pregnant women with broader doubts about other interventions.

“One of the concerns that we’re seeing now is that people aren’t sure who to trust and who the trusted messenger should be,” Hughes said, but medical societies are the most reliable sources of information.

“We are very careful about the science that we put into our guidelines,” she said. “We rigorously assess it for quality. We debate it to make sure that we think that the science is strong enough, and it is not one person making a decision or a recommendation. This is a committee of people with decades of expertise on these topics who really carefully look at the literature and ensure that we feel that it’s adequate before we make these recommendations.”

The-CNN-Wire
™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

World’s top humanoid maker and its dancing robots waltz towards record IPO listing in China

(CNN) — The world’s largest humanoid robot maker by sales is set to list in Shanghai on Wednesday, with the initial public offering already having raised 6.1 billion yuan ($905 million) and more than 8,000 times oversubscribed, a record for the city’s tech-focused STAR market, which is seen as China’s version of the Nasdaq.Having captured global attention with its dancing and kung-fu fighting androids, China’s Unitree has become the poster child of the country’s robotic advancement.On Monday, the Hangzhou-based company unveiled a new humanoid robot dubbed “Superman” which it said can jump as high as two metres and run at a speed of 12.66 metres per second.Unitree shot to national prominence last year after its robots took to China’s biggest stage, the annual Lunar New Year gala, with sleek dancing choreography. Since then, the company has emerged as a key strategic firm in the country’s ambition to dominate future technology, with its founder Wang Xingxing seated in the front row at President Xi Jinping’s rare symposium with top tech businesses last year.As China’s economic growth slows and its workforce shrinks, Beijing has bet billions of dollars on humanoid robots as the next disruptive product, seeing them as the “new high ground of technological competition and a fresh frontier for future industries,” according to a 2023 policy document.Getting ahead in the burgeoning industry could also boost China’s standing in the intensifying competition with the US on artificial intelligence and advanced technology.The market debut will make Unitree the first humanoid robot maker to be listed in mainland China. Other Chinese android firms, including UBTECH and Dobot, have been trading in Hong Kong, while Agibot, another frontrunner in the sector, is pursuing an IPO in the city.“Unitree IPO is regarded as a key milestone for the humanoid industry and can serve as a benchmark for other IPOs in the pipeline,” said Ethan Qi, associate director at market analysis firm Counterpoint Research.China already dominates humanoid robot sales globally. Last year, Chinese firms accounted for the vast majority of global android deliveries, far outpacing American competitors like Tesla, Figure AI and Boston Dynamics.However, the technology remains under both hardware and software constraints, with bipedal robots still years away from full-scale deployment, whether on factory floors or at home, experts say.For now, research and educational institution use accounted for the majority of Unitree’s sales, while industrial deployments remained less than 10% in the first three quarters of 2025, its earlier filing showed.“Unitree has demonstrated strong technology and commercial traction, but moving from demonstrations and early deployments to widespread industrial adoption will take time,” said Kangyuxiao Li, equity analyst at Morningstar, a financial services firm.Proceeds from the IPO, according to its prospectus, will be used for the research and development of embodied AI model and robot hardware, as well as factory expansion.Going gaga over UnitreeUnitree may not be a household name yet. But if you have scrolled past videos of human-like robots performing backflips or dancing to Lady Gaga’s Abracadabra on America’s Got Talent, you have likely seen the company’s products.Founded in China’s eastern tech hub of Hangzhou in 2016, Unitree is backed by several well-known Chinese companies, ranging from food delivery giant Meituan, tech mammoth Tencent, Alibaba and AI startup DeepSeek.Besides humanoid robots, the firm also makes quadrupled robots, known as robot dogs, which accounted for about 42% of its revenue last year.In just two years, its revenue skyrocketed more than 10 times to nearly 1.7 billion yuan ($252 million) in 2025, its prospectus showed.Unitree is also one of the few companies in the field which has achieved profitability, delivering a net profit of 278 million yuan ($41 million) last year.Last year, it delivered more than 5,500 humanoid robots across the world, making it the world’s largest seller of androids.Despite being a frontrunner in the industry, Qi of Counterpoint Research cautioned that Unitree’s edge appears to rely mostly on hardware and motion control capability, and that they need to beef up their research and development investment in embodied AI models, which serves as the machines’ brains.In an apparent bid to address such a weakness, a partnership between Unitree and US tech giant Nvidia was announced in June for research and development.Geopolitical restrictionsThe future of Unitree, however, hinges beyond its product competitiveness.In June, Unitree was added to the US government’s blacklist of Chinese military-linked companies and barred from doing business with the Pentagon.And last month, Washington banned new humanoid and quadruped robot imports from foreign manufacturers, calling them a national security risks – in a move aimed at China.While the restrictions do not cover existing models approved to be sold in the US, it could hurt future sales for companies like Unitree, particularly as over 40% of its revenue is generated overseas.Unitree has said in its prospectus that it “may be unable to sustain rapid growth in overseas sales and could even see its performance decline” if the US continues to impose restrictions.Beyond borders, Ming Lee, head of Greater China autos and industrials research at BofA Global Research, said Unitree also has to show it can successfully deploy its robots across various industry applications, and building up its embodied-AI system.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story